No abstract available
MeSH terms
-
Anticoagulants* / administration & dosage
-
Anticoagulants* / adverse effects
-
Anticoagulants* / therapeutic use
-
Antithrombins* / administration & dosage
-
Antithrombins* / adverse effects
-
Antithrombins* / therapeutic use
-
Dabigatran / administration & dosage
-
Dabigatran / adverse effects
-
Dabigatran / antagonists & inhibitors
-
Dabigatran / therapeutic use
-
Factor Xa Inhibitors* / administration & dosage
-
Factor Xa Inhibitors* / adverse effects
-
Factor Xa Inhibitors* / therapeutic use
-
Hemorrhage / chemically induced*
-
Hemorrhage / drug therapy
-
Humans
-
Neoplasms / complications
-
Perioperative Care
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyrazoles / antagonists & inhibitors
-
Pyrazoles / therapeutic use
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Pyridines / antagonists & inhibitors
-
Pyridines / therapeutic use
-
Pyridones / administration & dosage
-
Pyridones / adverse effects
-
Pyridones / antagonists & inhibitors
-
Pyridones / therapeutic use
-
Rivaroxaban / administration & dosage
-
Rivaroxaban / adverse effects
-
Rivaroxaban / antagonists & inhibitors
-
Rivaroxaban / therapeutic use
-
Thiazoles / administration & dosage
-
Thiazoles / adverse effects
-
Thiazoles / antagonists & inhibitors
-
Thiazoles / therapeutic use
-
Venous Thromboembolism / drug therapy*
-
Venous Thromboembolism / etiology
-
Venous Thromboembolism / prevention & control
-
Venous Thrombosis / drug therapy
-
Venous Thrombosis / etiology
-
Venous Thrombosis / prevention & control
Substances
-
Anticoagulants
-
Antithrombins
-
Factor Xa Inhibitors
-
Pyrazoles
-
Pyridines
-
Pyridones
-
Thiazoles
-
apixaban
-
Rivaroxaban
-
Dabigatran
-
edoxaban